Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
RSK 4 activation confers paclitaxel resistance in gastric cancer